Similar articles

• The mousetrap: managing the placebo effect in antidepressant trials.

  Lakoff A. Lakoff A. Mol Interv. 2002 Apr;2(2):72-6. doi: 10.1124/mi.2.2.72. Mol Interv. 2002. PMID: 14993352 Review. No abstract available.
• The enrichment window approach as a means of dealing with placebo response in antidepressant clinical trials.

  Mallinckrodt CH, Prucka WR. Mallinckrodt CH, et al. Clin Pharmacol Ther. 2010 Nov;88(5):592-4. doi: 10.1038/clpt.2010.222. Clin Pharmacol Ther. 2010. PMID: 20959845
• Effects of baseline depression severity on remission rates with duloxetine and placebo in anxious and nonanxious patients with major depression.

  Nelson JC. Nelson JC. J Clin Psychopharmacol. 2011 Oct;31(5):682-4. doi: 10.1097/JCP.0b013e31822bee26. J Clin Psychopharmacol. 2011. PMID: 21881463 No abstract available.
• The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.

  Griebel G, Beeské S, Stahl SM. Griebel G, et al. J Clin Psychiatry. 2012 Nov;73(11):1403-11. doi: 10.4088/JCP.12m07804. Epub 2012 Oct 16. J Clin Psychiatry. 2012. PMID: 23146246
• Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses.

  Sinyor M, Levitt AJ, Cheung AH, Schaffer A, Kiss A, Dowlati Y, Lanctôt KL. Sinyor M, et al. J Clin Psychiatry. 2010 Mar;71(3):270-9. doi: 10.4088/JCP.08r04516blu. Epub 2010 Jan 26. J Clin Psychiatry. 2010. PMID: 20122371 Review.